Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7067318
Methods for transfecting T cells
granted -
US 7067635
Nucleotide and deduced amino acid sequences of tumor gene Int6
granted -
US 7060276
Plasmodium falciparum AMA-1 protein and uses thereof
granted -
US 7056908
Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
granted -
US 7056734
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
granted -
US 7052907
Adult human dental pulp stem cells in vitro and in vivo
granted -
US 7052696
Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
granted -
US 7052904
Hybrid adeno-retroviral vector for the transfection of cells
granted -
US 7052703
T-cell receptorΞ³ alternate reading frame protein, (TARP) and uses thereof
granted -
US 7053243
3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same
granted -
US 7048935
Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
expired -
US 7049291
Isolation and method of using tissue growth-inducing Frzb protein
expired -
US 7045313
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
expired -
US 7045132
Streptococcus pneumoniae 37-kDa surface adhesin a protein
expired -
US 7045510
Methods for prevention and treatment of mastitis
expired -
US 7045336
Bacterial delivery system
expired -
US 7045136
Methods of immunization using recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences
expired -
US 7045675
Genes for Niemann-Pick type C disease
expired -
US 7041498
Method for modulating processes mediated by farnesoid activated receptors
expired -
US 7041503
Modified myelin basic protein molecules
expired -
US 7041296
Methods of treating inflammatory bowel disease using cholera toxin B subunit
expired -
US 7037680
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
expired -
US 7037499
Adjuvant for transcutaneous immunization
expired -
US 7033608
βBurst-freeβ sustained release poly-(lactide/glycolide) microspheres
expired -
US 7029899
Selective toxicity of amino-terminal modified rnase a superfamily polypeptides
expired -
US 7029685
Plasmodium falciparum AMA-1 protein and uses thereof
expired -
US 7026291
Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
expired -
US 7025963
Vaccine against Gram-negative bacterial infections
expired -
US 7026350
Water-soluble drugs and methods for their production
expired -
US 7025961
Anti-plasmodium composition and methods of use
expired -
US 7022315
Administration of a thiol-based chemoprotectant compound
expired -
US 7018636
Vaccine against Gram-negative bacterial infections
expired -
US 7015222
Agricultural compositions
expired -
US 7015024
Compositions containing recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences
expired -
US 7015212
Thiazepine inhibitors of HIV-1 integrase
expired -
US 7015312
Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
expired -
US 7009044
HCV/BVDV chimeric genomes and uses thereof
expired -
US 7009050
5-Substituted pyrimidine derivatives of conformationally locked nucleoside analogues
expired -
US 7001600
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
expired -
US 7001614
Liposome complexes for increased systemic delivery
expired -
US 6998252
Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences
expired -
US 6991793
Method of protecting fish against columnaris disease with modified live Flavobacterium columnare
expired -
US 6989370
Bacteriocins and novel bacterial strains
expired -
US 6987096
Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
expired -
US 6987176
Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
expired -
US 6987125
Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
expired -
US 6984504
Ebola virion proteins expressed from venezuelan equine encephalitis (VEE) virus replicons
expired -
US 6984388
Adhesion deficient isolate of Flavobacterium columnare against columnaris disease
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory